Nanni Huser Selected Research

Nanni Huser Research Topics

12	Neoplasms (Cancer) 10/2021 - 04/2009
2	Hematologic Neoplasms (Hematological Malignancy) 06/2017 - 07/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 09/2012
2	Hypoxia (Hypoxemia) 04/2012 - 12/2010
1	Breast Neoplasms (Breast Cancer) 10/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2012
1	Lymphoma (Lymphomas) 07/2012
1	Leukemia 07/2012
1	Ovarian Neoplasms (Ovarian Cancer) 04/2012

3	silmitasertibIBA 09/2012 - 12/2010
2	Proteins (Proteins, Gene)FDA Link 03/2021 - 04/2009
2	Biomarkers (Surrogate Marker)IBA 03/2021 - 04/2009
2	Immunoglobulin G (IgG)IBA 06/2017 - 01/2017
2	Casein Kinase II (Casein Kinase 2)IBA 09/2012 - 04/2012
2	ErbB Receptors (EGF Receptor)IBA 09/2012 - 04/2012
2	RNA Polymerase I (Polymerase I, RNA)IBA 07/2012 - 07/2012
2	CX 5461IBA 07/2012 - 07/2012
2	Ribosomal DNA (rDNA)IBA 07/2012 - 07/2012
1	palbociclibIBA 10/2021
1	Immune Checkpoint InhibitorsIBA 10/2021
1	Glucose (Dextrose)FDA LinkGeneric 03/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Gemtuzumab (Mylotarg)FDA Link 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Chemokine ReceptorsIBA 06/2017
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2017
1	Bendamustine Hydrochloride FDA Link 01/2017
1	Tyrosine Kinase InhibitorsIBA 09/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2012
1	Carboxylic AcidsIBA 07/2012
1	RNA (Ribonucleic Acid)IBA 07/2012
1	benzo(c)fluoreneIBA 07/2012
1	EnzymesIBA 07/2012
1	Drug CombinationsIBA 04/2012
1	Interleukin-6 (Interleukin 6)IBA 04/2012
1	Cisplatin (Platino)FDA LinkGeneric 04/2012
1	Gemcitabine FDA Link 04/2012
1	Oncogene Proteins (Oncogene Protein)IBA 04/2009
1	6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamineIBA 04/2009
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 04/2009
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 04/2009